GoAI
Get started
Jin Medical International Ltd. logo

Jin Medical International Ltd.

ZJYL

NASDAQHealthcareMedical - Instruments & Supplies

Open in GoAI

Previous close

$3.04

+$0.01 · +0.33%

Aug 21, 4:00 PM ET

Pre-market

$3.0595

+$0.0195 · +0.64%

Aug 24, 7:37 AM ET

ZJYL company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

51

Fair Value

Momentum

17

Strong Down

Sentiment

52

Mixed

Risk resilience

4

Extreme Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Jin Medical International Ltd. specializes in the conception, production, and worldwide distribution of mobility and daily living aids, including wheelchairs, for individuals with disabilities or restricted movement. Their product range additionally features oxygen concentrators and specialized bathing devices. Established in 2006, the company is headquartered in Changzhou, China, and operates as a subsidiary of Jolly Harmony Enterprises Limited.

Industry
Medical - Instruments & Supplies
Sector
Healthcare
Headquarters
CN
CEO
Erqi Wang
Listed since
Mar 28, 2023
Employees
273

Market position

Day range

Current $3.04

52-week range

Current $3.04

Open
$3.10
Previous close
$3.03
Volume
40.45K
0.09× average
Average volume
440.44K
Average daily volume
Market cap
23.8M USD
Beta
7.34
Market reference 1
50-day average
$2.319
+31.09% above average
200-day average
$2.9923
+1.59% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
99.9M USD
P/E (TTM)
20.79×
P/B (TTM)
0.78×
P/S (TTM)
1.21×
EV / EBITDA
107.09×
Earnings yield
1.35%
Free cash flow yield
-4.21%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
30.62%
Operating margin
2.12%
Net margin
5.94%
Return on equity
4.02%
Return on assets
2.23%
Return on invested capital
1.09%

Financial health

Debt / equity
0.68×
Current ratio
1.86×
Altman Z-score
2.45
Piotroski F-score
3 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends44%29%14%-1%Gross margin, FY2021: 30.64%Gross margin, FY2022: 32.30%Gross margin, FY2023: 34.23%Gross margin, FY2024: 40.43%Gross margin, FY2025: 29.22%Operating margin, FY2021: 12.67%Operating margin, FY2022: 11.10%Operating margin, FY2023: 14.47%Operating margin, FY2024: 15.48%Operating margin, FY2025: 2.94%Net margin, FY2021: 12.67%Net margin, FY2022: 14.10%Net margin, FY2023: 14.52%Net margin, FY2024: 15.64%Net margin, FY2025: 5.76%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 30.64%. Gross margin FY2022 32.30%. Gross margin FY2023 34.23%. Gross margin FY2024 40.43%. Gross margin FY2025 29.22%. Operating margin FY2021 12.67%. Operating margin FY2022 11.10%. Operating margin FY2023 14.47%. Operating margin FY2024 15.48%. Operating margin FY2025 2.94%. Net margin FY2021 12.67%. Net margin FY2022 14.10%. Net margin FY2023 14.52%. Net margin FY2024 15.64%. Net margin FY2025 5.76%.

Income trends

Revenue

20.69M USD-11.98%

Operating income

608.18K USD-83.29%

Net income

1.19M USD-67.59%
Income trends across reported periods25.79M USD16.63M USD7.48M USD−1.68M USDRevenue, FY2021: 20.76M USDRevenue, FY2022: 19.19M USDRevenue, FY2023: 19.82M USDRevenue, FY2024: 23.5M USDRevenue, FY2025: 20.69M USDOperating income, FY2021: 2.63M USDOperating income, FY2022: 2.13M USDOperating income, FY2023: 2.87M USDOperating income, FY2024: 3.64M USDOperating income, FY2025: 608.18K USDNet income, FY2021: 2.63M USDNet income, FY2022: 2.71M USDNet income, FY2023: 2.88M USDNet income, FY2024: 3.68M USDNet income, FY2025: 1.19M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 20.76M USD. Revenue FY2022 19.19M USD. Revenue FY2023 19.82M USD. Revenue FY2024 23.5M USD. Revenue FY2025 20.69M USD. Operating income FY2021 2.63M USD. Operating income FY2022 2.13M USD. Operating income FY2023 2.87M USD. Operating income FY2024 3.64M USD. Operating income FY2025 608.18K USD. Net income FY2021 2.63M USD. Net income FY2022 2.71M USD. Net income FY2023 2.88M USD. Net income FY2024 3.68M USD. Net income FY2025 1.19M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue20.69M USD23.5M USD19.82M USD19.19M USD20.76M USD
Cost of goods sold14.64M USD14M USD13.04M USD12.99M USD14.4M USD
Gross profit6.04M USD9.5M USD6.78M USD6.2M USD6.36M USD
Research and development1.56M USD1.5M USD1.54M USD1.89M USD1.57M USD
Selling, general, and administrative3.88M USD4.37M USD2.37M USD2.18M USD2.16M USD
Operating expenses5.44M USD5.86M USD3.92M USD4.07M USD3.73M USD
Interest income789.07K USD466.52K USD182.68K USD181.61K USD—
Interest expense————9.49K USD
Depreciation and amortization324.68K USD346.13K USD225.9K USD357.27K USD341.25K USD
Operating income608.18K USD3.64M USD2.87M USD2.13M USD2.63M USD
Net income1.19M USD3.68M USD2.88M USD2.71M USD2.63M USD

Company facts updated Aug 24, 2026.

Earnings

Latest EPS result
-0.01

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates0.20.120.03-0.05Q1 '26Q2 '26
Q1 2026, reported Jan 23, 2026: actual 0.16, estimate —, surprise —, Comparison unavailable. Q2 2026, reported May 11, 2026: actual -0.014, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly Revenue actual values compared with estimates11.24M10.32M9.4M8.49MQ1 '26Q2 '26
Q1 2026, reported Jan 23, 2026: actual 10.81M USD, estimate —, surprise —, Comparison unavailable. Q2 2026, reported May 11, 2026: actual 8.92M USD, estimate —, surprise —, Comparison unavailable.

ZJYL news

Corporate actions

Corporate action history

Stock split

Effective Mar 16, 2026

1:20

Stock split

Effective Feb 8, 2024

20:1

ZJYL peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

Continue in GoAI

Research ZJYL

research.disclaimer